Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Kain, Taylor ; Lindsay, Patrick J. ; Adhikari, Neill K.J. ; Arabi, Yaseen M. ; Van Kerkhove, Maria D. ; Fowler, Robert A.
• Description:
  Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). We conducted a systematic review of evidence for treatment with pharmacologic and supportive therapies. We developed a protocol and searched 5 databases for studies describing treatment of MERS and deaths in MERS patients. Risk of bias (RoB) was assessed by using ROBINS-I tool. We retrieved 3,660 unique citations; 20 observational studies met eligibility, and we studied 13 therapies. Most studies were at serious or critical RoB; no studies were at low RoB. One study, at moderate RoB, showed reduced mortality rates in severe MERS patients with extracorporeal membrane oxygenation; no other studies showed a significant lifesaving benefit to any treatment. The existing literature on treatments for MERS is observational and at moderate to critical RoB. Clinical trials are needed to guide treatment decisions.
• Subjects:
  Antiviral Agents Coronavirus Infections Humans Middle East Respiratory Syndrome Coronavirus
• Source:
  Emerg Infect Dis. 26(6):1102-1112
• Pubmed ID:
  32213260
• Pubmed Central ID:
  PMC7258456
• Document Type:
  Journal Article
• Volume:
  26
• Issue:
  6
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:439b9d286c446913a7d15237c0d0e0525f374765dbddee3a90451cceac8715da
• Download URL:
  https://stacks.cdc.gov/view/cdc/88892/cdc_88892_DS1.pdf
• File Type:
  [PDF - 604.95 KB ]